
Loading, please wait...

Loading, please wait...

Reactive oxygen species (ROS) govern essential cellular signaling pathways, immune defense responses, and pathological tissue destruction. Under normal physiological circumstances, complex biological systems regulate redox equilibrium with remarkable precision. However, when pathological insults overwhelm endogenous antioxidant defenses, severe oxidative stress promotes chronic inflammation, ischemic necrosis, or malignant cellular transformation. Consequently, developing targeted therapeutic delivery systems has become a central priority in translational medicine. In this regard, pH-responsive biomaterials provide an unprecedented platform to couple therapeutic redox interventions directly with localized disease conditions. Rather than acting as mere inert delivery vehicles, these advanced systems utilize tissue acidosis as a biologically relevant cue to execute on-demand drug release or catalytic radical conversion. Furthermore, integrating redox control with pathological pH fluctuations protects adjacent normal tissues while maximizing therapeutic efficacy at diseased sites.
Physiological extracellular tissue typically maintains a stable neutral pH between 7.35 and 7.45. In contrast, diverse pathological microenvironments exhibit severe disruptions in local proton homeostasis. In solid tumors, for example, aberrant metabolic reprogramming drives aerobic glycolysis, commonly termed the Warburg effect. Consequently, cancer cells pump excessive protons and lactic acid into the extracellular space, dropping local pH to values between 6.2 and 6.8. Similarly, acute ischemia, persistent bacterial infections, and non-healing diabetic ulcers generate markedly acidic niches due to vascular hypoperfusion and anaerobic bacterial metabolism. This localized acidosis fundamentally influences ROS generation, conversion, and clearance cascades. Specifically, elevated proton concentrations accelerate hydroxyl radical generation via Fenton chemistry while simultaneously destabilizing enzymatic cellular defenses. Furthermore, persistent oxidative stress damages cellular ion pumps, impairing systemic bicarbonate transport and worsening localized acidosis. Thus, tissue acidity and reactive radicals form a self-reinforcing pathogenic loop that perpetuates chronic inflammation and promotes tissue damage.
To exploit local acidosis, bioengineers formulate specialized pH-responsive biomaterials using sensitive chemical, biological, or supramolecular motifs. For instance, researchers extensively incorporate acid-labile covalent bonds into polymeric drug carriers. Bonds such as hydrazones, acetals, orthoesters, and benzoic imines exhibit excellent structural stability under neutral bloodstream conditions. However, upon encountering acidic interstitial environments, these linkages undergo accelerated hydrolytic cleavage, releasing encapsulated therapeutic cargo directly within the target tissue. Additionally, ionizable polymeric networks provide an efficient mechanism for conformational transitions. Polymers bearing tertiary amine or carboxylic acid groups experience alterations in protonation states across specific pH gradients. Consequently, changes in surface charge density trigger hydrophobic-to-hydrophilic phase shifts, driving rapid polymer swelling or nanocarrier dissolution. Furthermore, biomimetic peptides containing histidine residues undergo conformational unfolding in acidic milieus. Therefore, these versatile structural architectures grant clinicians precise control over the location, duration, and magnitude of therapeutic delivery, minimizing off-target adverse reactions across non-diseased tissue beds.
Effective disease remediation requires biomaterials to execute bidirectional redox modulation depending on the underlying pathology. In oncology, for instance, materials frequently amplify oxidative stress to trigger cancer cell death. Acidic intratumoral conditions induce the rapid disassembly of nanocarriers, releasing chemodynamic catalysts or photosensitizers. Subsequently, localized Fenton reactions generate destructive hydroxyl radicals that overwhelm tumor antioxidant defenses and eradicate resistant malignant cells. Conversely, inflammatory pathologies require powerful antioxidant activity to protect viable tissues. In chronic non-healing wounds, ischemic myocardial injuries, and inflammatory bowel diseases, excessive oxidative cascades prevent healing and destroy tissue matrices. Therefore, engineered hydrogels release antioxidant enzymes, small-molecule polyphenols, or Nrf2 activators selectively in response to acidic wound pH. Furthermore, smart polymeric surfaces expose catalytic radical-scavenging sites upon protonation. As a result, the biomaterial continuously consumes superoxides, hydrogen peroxide, and peroxynitrite. Ultimately, this targeted radical scavenging alleviates destructive oxidative stress, dampens persistent pro-inflammatory cytokine secretion, and accelerates tissue re-epithelialization.
Catalytic nanomaterials, widely known as nanozymes, represent a groundbreaking advance in artificial enzyme engineering. These inorganic nanoparticles exhibit intrinsic, enzyme-mimicking catalytic capabilities combined with robust operational stability. Remarkably, many metal-based nanozymes display pH-switchable catalytic behaviors. Under neutral physiological conditions, materials such as cerium oxide or iron oxide nanoparticles demonstrate superoxide dismutase and catalase activities. Consequently, they safely neutralize circulating radicals and preserve vascular endothelial integrity. In contrast, when exposed to an acidic tumor microenvironment, these nanozymes switch to peroxidase-like and oxidase-like activities. Therefore, they catalyze the breakdown of endogenous hydrogen peroxide into lethal hydroxyl radicals, promoting targeted tumor ablation. Moreover, single-atom catalysts and metal-organic frameworks maximize catalytic atom exposure, significantly elevating enzymatic efficiency. Injectable nanozyme-laden hydrogels also offer sustained local radical regulation without requiring frequent reapplication. Thus, these catalytic platforms overcome the thermal instability, immunogenicity, and high manufacturing costs associated with natural biological enzymes.
Despite impressive experimental successes, several translational hurdles hinder the clinical implementation of smart redox biomaterials. First, significant microenvironmental pH heterogeneity exists across different disease stages and patient cohorts. For instance, solid tumors often feature necrotic acidic centers surrounded by moderately perfused, neutral tissue zones, making uniform material activation difficult. Furthermore, biological fluids contain numerous proteins that immediately form a protein corona around circulating nanoparticles. This surface coating can obscure pH-sensitive chemical bonds and impede intended biodistribution. Additionally, researchers must thoroughly evaluate long-term biosafety, tissue accumulation, and clearance pathways. While biodegradable polymers degrade safely, inorganic nanozymes may accumulate within hepatic and splenic reticuloendothelial systems, raising toxicity concerns. Moreover, industrial manufacturing requires reproducible, large-scale synthesis protocols with strict batch-to-batch quality control. Overcoming these engineering challenges requires interdisciplinary collaboration between biomaterial scientists and clinicians. Ultimately, standardized validation protocols and clinically representative disease models will facilitate the safe translation of responsive redox biomaterials into routine practice.
Healthy tissues maintain an extracellular pH near 7.4 through strict physiological buffering systems. In contrast, pathological microenvironments such as tumors, ischemic lesions, and severe bacterial infections exhibit pronounced acidosis due to anaerobic glycolysis and localized hypoperfusion. Engineered biomaterials incorporate acid-cleavable bonds or protonatable chemical groups that remain stable at neutral pH. Upon encountering acidic tissue, these chemical components undergo selective degradation or conformational changes, thereby concentrating therapeutic activity solely at the disease site.
Nanozymes display catalytic plasticity that directly depends on the local hydronium ion concentration. Under neutral physiological conditions, many metal nanozymes exhibit catalase and superoxide dismutase activities, safely converting dangerous radicals into water and molecular oxygen. However, when exposed to the acidic milieu of tumor tissues, their catalytic profile shifts toward peroxidase and oxidase behaviors. Consequently, they accelerate Fenton-like reactions to generate toxic hydroxyl radicals that selectively induce apoptosis in malignant cells without harming normal tissues.
Clinical translation faces challenges in material uniformity, complex in vivo interactions, and physiological clearance. Synthesizing multi-component nanomaterials with reproducible physicochemical properties across large industrial batches remains technically challenging. Furthermore, non-specific protein adsorption in human plasma creates a dynamic biomolecular corona that frequently masks targeted functional motifs. Finally, non-biodegradable carrier matrices and metal-based nanoparticles risk long-term tissue bioaccumulation, requiring extensive pharmacokinetic evaluations and validated toxicological profiles before regulatory authorities grant approval for human administration.
Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.
References

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


Discover how pH-responsive biomaterials regulate reactive oxygen species to target tumor microenvironments, chronic wounds, and inflammatory lesions, offering new strategies for targeted therapy.
Today

A qualitative evaluation of the novel Weight History Interview highlights how capturing weight suppression informs eating disorder assessment while addressing patient emotional acceptability in clinical practice.
Today

Maternal codeine therapy during breastfeeding sparks debate regarding neonatal opioid toxicity. This review re-evaluates the Toronto case, explores PBPK modeling, and highlights how maternal and neonatal pharmacogenomics converge to inform safer postpartum pain management.
Today

The Food Safety and Standards Authority of India has challenged Red Bull over its marketing claims, demanding scientific evidence for the term energy drink. With products packing massive amounts of caffeine and added sugar, clinicians must recognize the critical cardiovascular and metabolic implications for young patients.
Today

A 491-patient cohort study in Sudan reveals critical insights into war trauma reconstructive surgery, analyzing injury patterns, soft-tissue procedures, and a 25.5% complication rate in resource-limited conflict zones.
Today

A multi-modal machine learning model integrating ultrasound radiomics, tumor morphology, TPO-Ab, and BRAF V600E accurately predicts lymph node metastasis in papillary thyroid carcinoma with concurrent Hashimoto's thyroiditis, achieving 0.879 accuracy.
Today